Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $416000.0.

  • CG Oncology's Depreciation & Amortization (CF) rose 188095.24% to $416000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $596000.0, marking a year-over-year increase of 155555.56%. This contributed to the annual value of $32000.0 for FY2024, which is 8823.53% up from last year.
  • As of Q3 2025, CG Oncology's Depreciation & Amortization (CF) stood at $416000.0, which was up 188095.24% from $156000.0 recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Depreciation & Amortization (CF) ranged from a high of $416000.0 in Q3 2025 and a low of $4000.0 during Q1 2023
  • Over the past 3 years, CG Oncology's median Depreciation & Amortization (CF) value was $6000.0 (recorded in 2023), while the average stood at $64500.0.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first changed by 0.0% in 2024, then surged by 212857.14% in 2025.
  • CG Oncology's Depreciation & Amortization (CF) (Quarter) stood at $4000.0 in 2023, then soared by 425.0% to $21000.0 in 2024, then surged by 1880.95% to $416000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $416000.0 in Q3 2025, compared to $156000.0 in Q2 2025 and $24000.0 in Q1 2025.